FENC Valuation

Fennec Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.680

+0.03(0.347%)1D

Overview
Forecast
Valuation
Earnings

FENC Relative Valuation

FENC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FENC is overvalued; if below, it's undervalued.

Historical Valuation

Fennec Pharmaceuticals Inc (FENC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.31 is considered Undervalued compared with the five-year average of 2.76. The fair price of Fennec Pharmaceuticals Inc (FENC) is between 27.98 to 29.82 according to relative valuation methord. Compared to the current price of 8.68 USD , Fennec Pharmaceuticals Inc is Undervalued By 68.98%.

Relative Value

Fair Zone

27.98-29.82

Current Price：8.68

68.98%

Undervalued

18.70

Trailing

Forward

10.42

EV/EBITDA

Fennec Pharmaceuticals Inc. (FENC) has a current EV/EBITDA of 10.42. The 5-year average EV/EBITDA is 3.42. The thresholds are as follows: Strongly Undervalued below -21.84, Undervalued between -21.84 and -9.21, Fairly Valued between 16.05 and -9.21, Overvalued between 16.05 and 28.68, and Strongly Overvalued above 28.68. The current Forward EV/EBITDA of 10.42 falls within the Historic Trend Line -Fairly Valued range.

16.95

EV/EBIT

Fennec Pharmaceuticals Inc. (FENC) has a current EV/EBIT of 16.95. The 5-year average EV/EBIT is 16.72. The thresholds are as follows: Strongly Undervalued below -142.00, Undervalued between -142.00 and -62.64, Fairly Valued between 96.07 and -62.64, Overvalued between 96.07 and 175.43, and Strongly Overvalued above 175.43. The current Forward EV/EBIT of 16.95 falls within the Historic Trend Line -Fairly Valued range.

4.31

Fennec Pharmaceuticals Inc. (FENC) has a current PS of 4.31. The 5-year average PS is 19.41. The thresholds are as follows: Strongly Undervalued below -57.67, Undervalued between -57.67 and -19.13, Fairly Valued between 57.95 and -19.13, Overvalued between 57.95 and 96.49, and Strongly Overvalued above 96.49. The current Forward PS of 4.31 falls within the Historic Trend Line -Fairly Valued range.

10.00

P/OCF

Fennec Pharmaceuticals Inc. (FENC) has a current P/OCF of 10.00. The 5-year average P/OCF is -35.96. The thresholds are as follows: Strongly Undervalued below -374.32, Undervalued between -374.32 and -205.14, Fairly Valued between 133.22 and -205.14, Overvalued between 133.22 and 302.39, and Strongly Overvalued above 302.39. The current Forward P/OCF of 10.00 falls within the Historic Trend Line -Fairly Valued range.

10.00

P/FCF

Fennec Pharmaceuticals Inc. (FENC) has a current P/FCF of 10.00. The 5-year average P/FCF is -29.88. The thresholds are as follows: Strongly Undervalued below -365.81, Undervalued between -365.81 and -197.84, Fairly Valued between 138.09 and -197.84, Overvalued between 138.09 and 306.06, and Strongly Overvalued above 306.06. The current Forward P/FCF of 10.00 falls within the Historic Trend Line -Fairly Valued range.

Fennec Pharmaceuticals Inc (FENC) has a current Price-to-Book (P/B) ratio of -32.14. Compared to its 3-year average P/B ratio of -23.14 , the current P/B ratio is approximately 38.90% higher. Relative to its 5-year average P/B ratio of -10.12, the current P/B ratio is about 217.63% higher. Fennec Pharmaceuticals Inc (FENC) has a Forward Free Cash Flow (FCF) yield of approximately -4.85%. Compared to its 3-year average FCF yield of 0.06%, the current FCF yield is approximately -8642.65% lower. Relative to its 5-year average FCF yield of -3.41% , the current FCF yield is about 42.24% lower.

-32.14

P/B

Median3y

-23.14

Median5y

-10.12

-4.85

FCF Yield

Median3y

0.06

Median5y

-3.41

Competitors Valuation Multiple

The average P/S ratio for FENC's competitors is 50.17, providing a benchmark for relative valuation. Fennec Pharmaceuticals Inc Corp (FENC) exhibits a P/S ratio of 4.31, which is -91.42% above the industry average. Given its robust revenue growth of 32.91%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FENC.O

Fennec Pharmaceuticals Inc

Amarin Corporation PLC

Tonix Pharmaceuticals Holding Corp

Capricor Therapeutics Inc

CytomX Therapeutics Inc

Loss

-25.71%

334.77M

Performance Decomposition

Market capitalization of FENC increased by 55.83% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -10.77 to -19.40.

The secondary factor is the Revenue Growth, contributed 32.91%to the performance.

Overall, the performance of FENC in the past 1 year is driven by P/E Change. Which is more unsustainable.

32.91%

7.26M → 9.65M

Revenue Growth

-57.29%

-76.47 → -32.66

Margin Expansion

80.21%

-10.77 → -19.40

P/E Change

55.83%